TY - JOUR
T1 - Group B streptococcus infection during pregnancy and infancy
T2 - estimates of regional and global burden
AU - Gonçalves, Bronner P.
AU - Procter, Simon R.
AU - Paul, Proma
AU - Chandna, Jaya
AU - Lewin, Alexandra
AU - Seedat, Farah
AU - Koukounari, Artemis
AU - Dangor, Ziyaad
AU - Leahy, Shannon
AU - Santhanam, Sridhar
AU - John, Hima B.
AU - Bramugy, Justina
AU - Bardají, Azucena
AU - Abubakar, Amina
AU - Nasambu, Carophine
AU - Libster, Romina
AU - Sánchez Yanotti, Clara
AU - Horváth-Puhó, Erzsébet
AU - Sørensen, Henrik T.
AU - van de Beek, Diederik
AU - Bijlsma, Merijn W.
AU - Gardner, William M.
AU - Kassebaum, Nicholas
AU - Trotter, Caroline
AU - GBS Danish and Dutch collaborative group for long term outcomes
AU - GBS Low and Middle Income Countries collaborative group for long term outcomes
AU - Bassat, Quique
AU - GBS Scientific Advisory Group, epidemiological sub-group
AU - Madhi, Shabir A.
AU - CHAMPS team
AU - Lambach, Philipp
AU - Jit, Mark
AU - Lawn, Joy E.
N1 - Funding Information:
The Department of Clinical Epidemiology of Aarhus University receives funding from private and public institutions in the form of institutional research grants to (and administered by) Aarhus University; none of these grants has any relation to the present study. SAM declares funding from Astrazeneca, the Bill & Melinda Gates Foundation, GlaxoSmithKline, Minervax, Novavax, Pfizer, and the South Africa Medical Research Council; in particular, SAM delares funding to his institution from Pfizer for epidemiology studies on group B streptococcus (GBS) and a clinical trial on the GBS vaccine, and from the Bill & Melinda Gates Foundation on GBS epidemiology. FS declares employment by the UK National Screening Committee, which developed the policy recommendation for maternal GBS screening. CT declares a consulting fee from WHO for drafting a report on the Full Value of Vaccine Assessment for GBS vaccines, which is related to the current manuscript. RL declares participation on an advisory board for Janssen and Pfizer; payment for lectures from Reckitt; and grants to Fundación INFANT from the Bill & Melinda Gates Foundation and PATH. All other authors declare no competing interests.
Funding Information:
We thank the teams working in the CHAMPS network, that provided data allowing us to update our estimates on stillbirths caused by GBS infection. We are also grateful to members of the project's Scientific Advisory Group. We thank Simon Cousens for insightful advice on epidemiological variables. We are grateful to the authors of the previous estimation work for advice regarding previous input datasets, notably Fiorella Bianchi and Neal Russell. We thank Claudia da Silva for administrative support. The findings and conclusions in this report are those of the authors, and do not necessarily represent the official position of any of the agencies or organisations listed. In particular, the findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. This work was supported by a grant (number OPP1180644) from the Bill & Melinda Gates Foundation to the London School of Hygiene & Tropical Medicine (principal investigator, Joy Lawn). The Bill & Melinda Gates Foundation also provided financial support to the WHO Immunization, Vaccines, and Biologicals department (grant number INV-1175247). PL works for WHO. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy, or views of WHO.
Publisher Copyright:
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Background: Group B streptococcus (GBS) colonisation during pregnancy can lead to invasive GBS disease (iGBS) in infants, including meningitis or sepsis, with a high mortality risk. Other outcomes include stillbirths, maternal infections, and prematurity. There are data gaps, notably regarding neurodevelopmental impairment (NDI), especially after iGBS sepsis, which have limited previous global estimates. In this study, we aimed to address this gap using newly available multicountry datasets. Methods: We collated and meta-analysed summary data, primarily identified in a series of systematic reviews published in 2017 but also from recent studies on NDI and stillbirths, using Bayesian hierarchical models, and estimated the burden for 183 countries in 2020 regarding: maternal GBS colonisation, iGBS cases and deaths in infants younger than 3 months, children surviving iGBS affected by NDI, and maternal iGBS cases. We analysed the proportion of stillbirths with GBS and applied this to the UN-estimated stillbirth risk per country. Excess preterm births associated with maternal GBS colonisation were calculated using meta-analysis and national preterm birth rates. Findings: Data from the seven systematic reviews, published in 2017, that informed the previous burden estimation (a total of 515 data points) were combined with new data (17 data points) from large multicountry studies on neurodevelopmental impairment (two studies) and stillbirths (one study). A posterior median of 19·7 million (95% posterior interval 17·9–21·9) pregnant women were estimated to have rectovaginal colonisation with GBS in 2020. 231 800 (114 100–455 000) early-onset and 162 200 (70 200–394 400) late-onset infant iGBS cases were estimated to have occurred. In an analysis assuming a higher case fatality rate in the absence of a skilled birth attendant, 91 900 (44 800–187 800) iGBS infant deaths were estimated; in an analysis without this assumption, 58 300 (26 500–125 800) infant deaths from iGBS were estimated. 37 100 children who recovered from iGBS (14 600–96 200) were predicted to develop moderate or severe NDI. 40 500 (21 500–66 200) maternal iGBS cases and 46 200 (20 300–111 300) GBS stillbirths were predicted in 2020. GBS colonisation was also estimated to be potentially associated with considerable numbers of preterm births. Interpretation: Our analysis provides a comprehensive assessment of the pregnancy-related GBS burden. The Bayesian approach enabled coherent propagation of uncertainty, which is considerable, notably regarding GBS-associated preterm births. Our findings on both the acute and long-term consequences of iGBS have public health implications for understanding the value of investment in maternal GBS immunisation and other preventive strategies. Funding: Bill & Melinda Gates Foundation.
AB - Background: Group B streptococcus (GBS) colonisation during pregnancy can lead to invasive GBS disease (iGBS) in infants, including meningitis or sepsis, with a high mortality risk. Other outcomes include stillbirths, maternal infections, and prematurity. There are data gaps, notably regarding neurodevelopmental impairment (NDI), especially after iGBS sepsis, which have limited previous global estimates. In this study, we aimed to address this gap using newly available multicountry datasets. Methods: We collated and meta-analysed summary data, primarily identified in a series of systematic reviews published in 2017 but also from recent studies on NDI and stillbirths, using Bayesian hierarchical models, and estimated the burden for 183 countries in 2020 regarding: maternal GBS colonisation, iGBS cases and deaths in infants younger than 3 months, children surviving iGBS affected by NDI, and maternal iGBS cases. We analysed the proportion of stillbirths with GBS and applied this to the UN-estimated stillbirth risk per country. Excess preterm births associated with maternal GBS colonisation were calculated using meta-analysis and national preterm birth rates. Findings: Data from the seven systematic reviews, published in 2017, that informed the previous burden estimation (a total of 515 data points) were combined with new data (17 data points) from large multicountry studies on neurodevelopmental impairment (two studies) and stillbirths (one study). A posterior median of 19·7 million (95% posterior interval 17·9–21·9) pregnant women were estimated to have rectovaginal colonisation with GBS in 2020. 231 800 (114 100–455 000) early-onset and 162 200 (70 200–394 400) late-onset infant iGBS cases were estimated to have occurred. In an analysis assuming a higher case fatality rate in the absence of a skilled birth attendant, 91 900 (44 800–187 800) iGBS infant deaths were estimated; in an analysis without this assumption, 58 300 (26 500–125 800) infant deaths from iGBS were estimated. 37 100 children who recovered from iGBS (14 600–96 200) were predicted to develop moderate or severe NDI. 40 500 (21 500–66 200) maternal iGBS cases and 46 200 (20 300–111 300) GBS stillbirths were predicted in 2020. GBS colonisation was also estimated to be potentially associated with considerable numbers of preterm births. Interpretation: Our analysis provides a comprehensive assessment of the pregnancy-related GBS burden. The Bayesian approach enabled coherent propagation of uncertainty, which is considerable, notably regarding GBS-associated preterm births. Our findings on both the acute and long-term consequences of iGBS have public health implications for understanding the value of investment in maternal GBS immunisation and other preventive strategies. Funding: Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85129520694&partnerID=8YFLogxK
U2 - 10.1016/S2214-109X(22)00093-6
DO - 10.1016/S2214-109X(22)00093-6
M3 - Article
C2 - 35490693
SN - 2214-109X
VL - 10
SP - e807-e819
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 6
ER -